Impact BioMedical (IBO) Q4 2025 earnings summary

Executive summary

• Expanded intellectual property portfolio to 60 issued and 60+ pending patents, including new allowances for Laetose and 3F technologies in Europe and the U.S.

• Acquired Celios Air Purification technology, enhancing product offerings and positioning for near-term revenue.

• Entered a definitive merger agreement with Dr. Ashleys Limited, combining pharmaceutical manufacturing and IP portfolios.

• Settled $15 million in debt to DSS, Inc. via equity conversion, strengthening the balance sheet.

Financial highlights

• Revenue for 2025 was $32,000, all from Celios air purification technology retail sales, a new product line.

• Net loss for 2025 was $11.87 million, a 52% improvement from $24.77 million in 2024.

• Total costs and expenses decreased 85% year-over-year to $4.31 million, mainly due to the absence of goodwill impairment in 2025.

• Cash and cash equivalents at year-end 2025 were $3,000, down from $1.999 million in 2024.

• Operating cash outflow improved to $1.89 million from $2.85 million in 2024.

Outlook and guidance

• Management plans to monetize intellectual property and control costs to address going concern risks.

• Exploring capital raises and debt financing to support ongoing operations.

• Strategic merger with Dr. Ashleys Limited expected to accelerate revenue generation and product development.